Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. - Wikidata - awgldk - TriplyDB

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

http://www.wikidata.org/entity/Q48964664

about

Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors Hsp70.1 and related lysosomal factors for necrotic neuronal death Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29 Impact of temperature dependent sampling procedures in proteomics and peptidomics--a characterization of the liver and pancreas post mortem degradome Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition.Glutathione-S-transferase P1 is a critical regulator of Cdk5 kinase activity Activation of latent cyclin-dependent kinase 5 (Cdk5)-p35 complexes by membrane dissociation Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39 Cdk5 is a New Rapid Synaptic Homeostasis Regulator Capable of Initiating the Early Alzheimer-Like Pathology.Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis.Identification of small molecule inhibitors of beta-amyloid cytotoxicity through a cell-based high-throughput screening platform.Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression.Cdk5 activity in the brain - multiple paths of regulation.No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro.A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains.A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.Increased synaptophysin is involved in inflammation-induced heat hyperalgesia mediated by cyclin-dependent kinase 5 in rats.TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level.Cdk5 protein inhibition and Aβ42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease.Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neurons.Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better?Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain.Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias Loss of DARPP-32 and calbindin in multiple system atrophy.Silencing of CDK5 as potential therapy for Alzheimer's disease.Generation of the Cdk5 activator p25 is a memory mechanism that is affected in early Alzheimer's disease.The Role of Cdk5 in Alzheimer's Disease.Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses.Calpain research for drug discovery: challenges and potential.Relative resistance of Cdk5-phosphorylated CRMP2 to dephosphorylation.Calpain Activation in Alzheimer's Model Mice Is an Artifact of APP and Presenilin Overexpression.Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer's disease.A pool of beta-tubulin is hyperphosphorylated at serine residues in Alzheimer disease brain.Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS.The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties.An anti-CAPN5 intracellular antibody acts as an inhibitor of CAPN5-mediated neuronal degeneration.

P2860

Q24657243-AD2F9D3F-8AB6-429B-B0B2-1DC7BA03C6EA Q26771736-21935FAA-6CBD-4275-9BAF-3711EA65B798 Q27012978-03E8BCB1-6E3E-4A41-8F1D-3FE4F2107488 Q28208444-94FBAE89-5492-4FC1-B395-A27D707AEBC1 Q28215152-E2D95BA6-40CB-4268-9C75-BC7266F36B5F Q28386567-68C50D7D-2A3B-47F4-834A-F5321112A68E Q28391148-AACE7531-FFBB-4908-B0E2-BE73FC9D09DD Q28565510-6B0A5210-5C98-4269-B7E4-7212C762BBEB Q28566550-25FC42A7-8520-4A45-BE92-4AB89D84B7D8 Q28574229-3A812580-5281-4D32-B064-F367059969C8 Q30279162-BACD1F50-62A6-4CE1-AB69-735CAEFB465C Q33353893-6A00210A-026C-46C7-92EF-C46170EA7A12 Q33371464-E7B3CEE7-3212-4848-BA73-6350031C8673 Q33640651-7C884B58-81E4-47D4-9814-6426DC0FE9B6 Q33687591-23F14DD5-1A81-4DA9-AA0E-A80FC659B2A2 Q33733724-F91AF2CA-6BF4-4E27-A99E-C5E72D0C14C8 Q34139509-22F6746D-0A52-4B26-BAED-8A1CDE7DC9CA Q34232193-A2E8EC40-6827-4784-85C4-6192102C036C Q34441821-4F78DB40-4087-444A-BA33-A90B71A3748F Q34549221-6CFE50D5-DD8E-49A9-B436-A75414082965 Q35016882-6D0E5359-4B3B-435F-AF5D-D6802352D3F5 Q35191074-93B90529-0792-4740-8451-FA5E06393E33 Q35801936-B28E7CAB-62F4-4EA6-8A19-BAE5203DF225 Q36234524-54C8A0C0-A450-4220-8869-C5C7DB3A5565 Q36266206-F01FBF3A-79B6-4BF4-9CF3-4F4C8FFE5330 Q36758446-7D0DF986-4B79-4D33-89CA-25D82227F06A Q37243713-214D5DF6-8DC5-4005-99B8-04828423EA28 Q37325736-39434824-9CF8-4A6C-90BB-E85D47F150B5 Q37863144-3B70CB96-DD20-449F-926F-FB4FF3FE1A9A Q38211426-504C40FB-5DC1-44F3-B96F-F0500185A5CD Q38557958-79557DAC-62C0-40D8-9118-7F993F46849C Q38587949-B27605C0-C9A6-4E5C-A6DB-D953089AD5A8 Q39004902-951FF2E9-E346-45F7-950C-673DDD1D98BE Q39599528-8A411246-6E19-4597-87E5-08E3C911CC06 Q41138030-47409167-89B0-4224-A569-E00602A8ECD2 Q41438444-5DA35FC3-4499-44B8-85A7-203806883AD4 Q43828064-600FB82E-139B-4FF0-82DF-53E893D7A39A Q46461914-DC1B7D55-D21F-4BDE-9DFE-A734EC482F51 Q46669000-8D8024E1-36A8-4CA5-98E8-3225173263C0 Q47136494-ADEBA4B2-EECC-4AE9-9AFB-C59186DF77EA

P2860

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

http://www.wikidata.org/entity/Q48964664

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

@en

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

@nl

type

label

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

@en

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

@nl

prefLabel

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

@en

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

@nl

P1433

Q48964664-01BDCC3D-6BBF-4CA3-A77C-6F0A4F5BD80D

P1476

Q48964664-780C2916-87B7-40EA-AF3B-E45A0B4EFFEC

P2093

Q48964664-02CD8EF0-7E8B-4609-86CE-27C2E7ACAE06

Q48964664-0724C464-0A92-4721-8AFC-9C354FA2A13C

Q48964664-1C2B3DA5-2D96-47AE-AF88-50E7AE4E78B2

Q48964664-2338928F-ABDB-4CC3-97BC-030DFF5E33AE

Q48964664-255DE5C1-5E80-47BD-92F5-6B4F7C08DEB9

Q48964664-26DBE719-EF90-4F43-AC38-FB38F4BC807F

Q48964664-4FDA49C3-F9CC-476B-9466-1766F9B33ADC

Q48964664-BDC78293-2F68-44A9-AE30-4783382A9804

Q48964664-C7C87B54-33AB-42E5-AFF3-E81ACE974BFB

Q48964664-D50DC298-F69D-45D5-A204-78A3141F4B90

P304

Q48964664-479A450C-9AD0-4CD3-8F31-06CC440D9CA6

P31

Q48964664-52639043-AD89-477D-996C-10DDA1B2D997

P356

Q48964664-BBC88794-133E-4783-A3C9-FCD50F9BF02A

P407

Q48964664-2CDB4AD9-81CB-4426-8575-1729596881FD

P433

Q48964664-696D07D0-FF8B-4512-A85C-84C695131264

P478

Q48964664-076358A9-61B3-42F9-AF93-F90604CEDE57

P577

Q48964664-5746687E-35CD-451E-BAE0-AA1E10B966C6

P5875

Q48964664-C2A228B6-9812-4027-A746-7F4D8BDBBCB4

P698

Q48964664-771843D5-C3EE-4875-B9E6-9C6A41AA93DA

P356

S0014-5793(00)02431-5

P1433

P1476

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

@en

P2093

Fujita Y

http://www.w3.org/2001/XMLSchema#string

Hasegawa M

http://www.w3.org/2001/XMLSchema#string

Hayashi S

http://www.w3.org/2001/XMLSchema#string

Hisanaga S

http://www.w3.org/2001/XMLSchema#string

Iwatsubo T

http://www.w3.org/2001/XMLSchema#string

Kakita A

http://www.w3.org/2001/XMLSchema#string

Murayama S

http://www.w3.org/2001/XMLSchema#string

Saido TC

http://www.w3.org/2001/XMLSchema#string

Takahashi H

http://www.w3.org/2001/XMLSchema#string

Taniguchi S

http://www.w3.org/2001/XMLSchema#string

P304

46-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0014-5793(00)02431-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

489

http://www.w3.org/2001/XMLSchema#string

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12100773

http://www.w3.org/2001/XMLSchema#string

P698

11231011

http://www.w3.org/2001/XMLSchema#string